Geron (GERN) Operating Expenses (2010 - 2026)
Geron (GERN) posted Operating Expenses of $51.7 million for Q1 2026, down 79.25% sequentially from $249.0 million in Q4 2025, and down 8.22% YoY from $56.3 million in Q1 2025.
Geron (GERN) Operating Expenses (2010 - 2026) Analysis & Trends
Geron has reported Operating Expenses for 17 years, with the latest figure at $51.7 million in Q1 2026.
- Quarterly Operating Expenses fell 8.22% year-over-year to $51.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $423.3 million (up 38.05% YoY) and the FY2025 annual result came in at $252.5 million, up 0.69% from the prior year.
- Operating Expenses eased to $51.7 million in Q1 2026 per GERN's latest filing, from $249.0 million in the prior quarter.
- Over five years, Operating Expenses peaked at $250.3 million in Q4 2024 and troughed at -$139.9 million in Q4 2023.
- A 5-year average of $54.4 million and a median of $51.7 million in 2026 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses plunged 432.59% in 2023, then surged 278.92% in 2024.
- Over 5 years, Operating Expenses stood at $42.1 million in 2022, then slumped by 432.59% to -$139.9 million in 2023, then soared by 278.92% to $250.3 million in 2024, then declined by 0.49% to $249.0 million in 2025, then slumped by 79.25% to $51.7 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $51.7 million, $249.0 million, and $61.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Geron | 1.04 Mn | -299.81 Mn | - | 69.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 69.98 Mn |
| Mar 31, 2026 | 51.68 Mn |
| Dec 31, 2025 | 249.03 Mn |
| Sep 30, 2025 | 61.11 Mn |
| Jun 30, 2025 | 61.49 Mn |
| Mar 31, 2025 | 56.31 Mn |
| Dec 31, 2024 | 250.25 Mn |
| Sep 30, 2024 | 56.49 Mn |
| Jun 30, 2024 | -56.42 Mn |
| Mar 31, 2024 | 56.44 Mn |
| Dec 31, 2023 | -139.87 Mn |
| Sep 30, 2023 | 47.78 Mn |
| Jun 30, 2023 | 51.98 Mn |
| Mar 31, 2023 | 40.11 Mn |
| Dec 31, 2022 | 42.05 Mn |
| Sep 30, 2022 | 40.25 Mn |
| Jun 30, 2022 | 28.05 Mn |
| Mar 31, 2022 | 28.80 Mn |
| Dec 31, 2021 | 32.02 Mn |
| Sep 30, 2021 | 25.78 Mn |